T cell responses to myelin proteins in Guillain-Barré syndrome

1992 ◽  
Vol 111 (2) ◽  
pp. 200-203 ◽  
Author(s):  
A. Khalili-Shirazi ◽  
R.A.C. Hughes ◽  
S.W. Brostoff ◽  
C. Linington ◽  
N. Gregson
1991 ◽  
Vol 35 ◽  
pp. 55
Author(s):  
A. Khalili-Shirazi ◽  
N.A. Gregson ◽  
R.A.C. Hughes ◽  
S.W. Brostoff ◽  
C. Linington

1997 ◽  
Vol 145 (2) ◽  
pp. 169-176 ◽  
Author(s):  
A Khalili-Shirazi ◽  
N.A Gregson ◽  
M.A Hall ◽  
R.A.C Hughes ◽  
J.S Lanchbury

2005 ◽  
Vol 12 (4) ◽  
pp. 409-415 ◽  
Author(s):  
Peter A. Csurhes ◽  
Alice-Ann Sullivan ◽  
Kerryn Green ◽  
Judith M. Greer ◽  
Michael P. Pender ◽  
...  

2021 ◽  
Author(s):  
Yang Sun ◽  
Yanjun Guo ◽  
Yaqing Wu ◽  
Ningning Luo ◽  
Xinjia He

Abstract Immunotherapy combinations have changed the treatment paradigm of advanced renal cell carcinoma (RCC). Notably, immunotherapy induces a new spectrum of immune-related adverse events (irAEs). Guillain–Barré syndrome (GBS) is a rare and potentially fatal nervous system irAE. The activation of T-cell is considered a triggering factor of GBS. We herein reported a case of GBS-like syndrome during treatment of tislelizumab and axitinib in a patient with RCC. To our knowledge, this is the first report of tislelizumab-related GBS.


2007 ◽  
Vol 188 (1-2) ◽  
pp. 143-145 ◽  
Author(s):  
Nizar Souayah ◽  
Nimer F. Mian ◽  
Yajuan Gu ◽  
Amjad A. Ilyas

Neurology ◽  
2003 ◽  
Vol 61 (7) ◽  
pp. 994-996 ◽  
Author(s):  
I. Van Rhijn ◽  
T. Logtenberg ◽  
C. W. Ang ◽  
L. H. Van den Berg

Neurology ◽  
1998 ◽  
Vol 51 (2) ◽  
pp. 379-384 ◽  
Author(s):  
J. J. Ma ◽  
M. Nishimura ◽  
H. Mines ◽  
S. Kuroki ◽  
M. Nukina ◽  
...  

Objective: We examined a possible involvement of genetic factors influencing the development of Guillain-Barré syndrome (GBS).Methods: We studied T-cell receptor (TCR), alpha-chain constant (AC), and beta-chain variable (BV) gene polymorphisms using microsatellite markers and serologic HLA class I antigens, HLA-DRB1, and HLA-DQB1 alleles in 81 Japanese patients with GBS and 87 controls.Results: There were no significant differences in these genetic markers between GBS patients and controls. Subgrouping of GBS patients according to recent Campylobacter jejuni infection, the presence of anti-GM1 antibody in the sera, or their combinations also failed to reveal significant associations with these genetic markers. There was, however, a tendency for an increased frequency of HLA-DRB1*0803 in the C. jejuni + GM1 + GBS group, when compared with controls.Conclusions: The data suggest that the roles of TCRAC, T-cell receptor beta-chain variable (TCRBV), HLA class I or class II in the development of GBS are not critical, and further research is necessary to clarify other genes encoded within the HLA region for genetic susceptibility to GBS.


2010 ◽  
Vol 34 (7) ◽  
pp. e154-e156 ◽  
Author(s):  
Kamal K.S. Abbi ◽  
Syed M. Rizvi ◽  
Jeffrey Sivik ◽  
Subramanian Thyagarajan ◽  
Thomas Loughran ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document